Strategic collaboration Promed-Maintrix in cosmetics

Promed, a leading innovator in collagen biomaterials, has announced its strategic collaboration with Maintrix, a prominent cosmeceuticals manufacturer.

“This collaboration marks an important step forward in skincare technology and reinforces Promed's dedication to excellence in the medical cosmetics sector,” Promed said in a press release.

It added that the partnership signifies a shared commitment to advancing skincare products utilising CollX3, Promed's proprietary water-soluble triple atelocollagen complex. Anticipated for release in 2024, this collaboration aims to bring innovative medical skincare solutions to consumers while respecting each company's expertise and confidentiality.

CollX3 represents a breakthrough in collagen technology, offering exceptional benefits for skincare formulations. As the first European water-soluble atelocollagen complex, CollX3 boasts optimal blending characteristics and a unique peptide complex profile. Its ability to penetrate deeply into the skin promotes wound healing, stimulates collagen and elastin production, and facilitates skin regeneration, setting a new standard for skincare excellence.

"We are thrilled to have Maintrix join the group of customers that have trusted us," said Costas Pitsillides, Promed’s CEO.

The collaboration between Promed and Maintrix aligns with market trends and consumer demands, particularly in the area of skin regeneration.

"We are excited about this collaboration with Promed," said Panagiotis Panayi, CEO at Maintrix. "The exceptional quality and efficacy of CollX3 perfectly complements our commitment to delivering premium skincare solutions."

“As part of Promed's broader strategy for growth and innovation within the medical cosmetics industry, this collaboration reinforces the company's position as a trusted supplier of collagen biomaterials of the highest quality for skincare excellence,” the press release concluded.